BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 2021;84:1254-68. [PMID: 33422626 DOI: 10.1016/j.jaad.2020.12.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Talamonti M, Galluzzo M. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents. Expert Opin Biol Ther 2021;:1-3. [PMID: 34357839 DOI: 10.1080/14712598.2021.1965985] [Reference Citation Analysis]
2 Cazzaniga S, Naldi L. Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic. Br J Dermatol 2021. [PMID: 34726776 DOI: 10.1111/bjd.20776] [Reference Citation Analysis]
3 Niebel D, Novak N, Wilhelmi J, Ziob J, Wilsmann-Theis D, Bieber T, Wenzel J, Braegelmann C. Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. Vaccines (Basel) 2021;9:944. [PMID: 34579181 DOI: 10.3390/vaccines9090944] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, Myers B, Shi ZR, Yosipovitch G, Bell S, Liao W. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. J Invest Dermatol 2021:S0022-202X(21)01007-1. [PMID: 33888321 DOI: 10.1016/j.jid.2021.02.743] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kamiya K, Komine M, Ohtsuki M. Biologics for Psoriasis during the COVID-19 Pandemic. J Clin Med 2021;10:1390. [PMID: 33808455 DOI: 10.3390/jcm10071390] [Reference Citation Analysis]
6 Mintoff D, Chatterjee M, Podder I, Shipman A, Das A. Clinical Dermatology and COVID-19 Pandemic: Narrative Review. Indian J Dermatol 2021;66:246-55. [PMID: 34446947 DOI: 10.4103/ijd.ijd_463_21] [Reference Citation Analysis]
7 Zeng H, Wang S, Chen L, Shen Z. Biologics for Psoriasis During the COVID-19 Pandemic. Front Med (Lausanne) 2021;8:759568. [PMID: 34938746 DOI: 10.3389/fmed.2021.759568] [Reference Citation Analysis]
8 Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, Schett G. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724-36. [PMID: 34485930 DOI: 10.1016/S2665-9913(21)00247-2] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mintoff D, Benhadou F. Guselkumab does not appear to influence the IgG antibody response to SARS-CoV-2. Dermatol Ther 2021;:e15246. [PMID: 34865295 DOI: 10.1111/dth.15246] [Reference Citation Analysis]
10 Gondo GC, Bell SJ, Slayden J, Ullmann G, Blauvelt A. Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. J Eur Acad Dermatol Venereol 2021;35:e354-5. [PMID: 33587770 DOI: 10.1111/jdv.17173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ninosu N, Roehrich F, Diehl K, Peitsch WK, Schaarschmidt ML. Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital. Eur J Dermatol 2021;31:183-91. [PMID: 33871361 DOI: 10.1684/ejd.2021.4016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fatani MIA, Hamadah IRA, Alajlan MA, Binamer Y, Alharbi AHS, Alruwaili AFS, Aldayel MAA, Alenzi KAO, Mubarki SM, Khardaly AM, Alomari BAA, Almudaiheem HY, Al-Jedai A, Eshmawi MTY. Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). J Dermatolog Treat 2021;:1-15. [PMID: 34284704 DOI: 10.1080/09546634.2021.1950601] [Reference Citation Analysis]
13 Skroza N, Bernardini N, Tolino E, Proietti I, Mambrin A, Marchesiello A, Marraffa F, Rossi G, Volpe S, Potenza C. Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. J Clin Med 2021;10:3355. [PMID: 34362136 DOI: 10.3390/jcm10153355] [Reference Citation Analysis]
14 Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol 2021. [PMID: 34310699 DOI: 10.1111/bjd.20659] [Reference Citation Analysis]
15 Ayatollahi A, Hosseini H, Firooz R, Firooz A. COVID-19 vaccines: What dermatologists should know? Dermatol Ther 2021;:e15056. [PMID: 34232548 DOI: 10.1111/dth.15056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
17 Musumeci ML, Caruso G, Trecarichi AC, Micali G. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience. Dermatol Ther 2021;:e15177. [PMID: 34699117 DOI: 10.1111/dth.15177] [Reference Citation Analysis]
18 El-Komy MHM, Abdelnaby A, El-Kalioby M. How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross-sectional survey study. J Cosmet Dermatol 2021;20:1573-9. [PMID: 33811728 DOI: 10.1111/jocd.14104] [Reference Citation Analysis]
19 Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol 2021. [PMID: 34365714 DOI: 10.1111/jocd.14381] [Reference Citation Analysis]
20 Butt M, Marks JG Jr, Flamm A. Establishing Consensus on the Treatment of Toxicodendron Dermatitis. Dermatitis 2022. [PMID: 35481848 DOI: 10.1097/DER.0000000000000894] [Reference Citation Analysis]
21 Waldman RA, Grant-Kels JM. Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations. J Am Acad Dermatol 2021;85:1113-6. [PMID: 34437985 DOI: 10.1016/j.jaad.2021.08.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, Mariotti EB, Corrà A, Aimo C, Quintarelli L, Verdelli A, Li Gobbi F, Antiga E, Caproni M. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? Front Med 2022;9:811829. [DOI: 10.3389/fmed.2022.811829] [Reference Citation Analysis]
23 Rosi E, Fastame MT, Di Cesare A, Silvi G, Pimpinelli N, Prignano F. Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic. J Clin Med 2021;10:5841. [PMID: 34945136 DOI: 10.3390/jcm10245841] [Reference Citation Analysis]
24 Stingeni L, Bianchi L, Peris K, Fabbrocini G, Micali G, Calzavara-Pinton P, Tramontana M, Hansel K; Board Members of SIDeMaST. SARS-CoV-2 vaccines and biological treatments: dermatological perspectives. Ital J Dermatol Venerol 2021;156:118-20. [PMID: 33960748 DOI: 10.23736/S2784-8671.21.07055-9] [Reference Citation Analysis]
25 Hammam N, Tharwat S, Shereef RRE, Elsaman AM, Khalil NM, Fathi HM, Salem MN, El-Saadany HM, Samy N, El-Bahnasawy AS, Abdel-Fattah YH, Amer MA, ElShebini E, El-Shanawany AT, El-Hammady DH, Noor RA, ElKhalifa M, Ismail F, Fawzy RM, El-Najjar AR, Selim ZI, Abaza NM, Radwan AR, Elazeem MI, Mohsen WA, Moshrif AH, Mohamed EF, Aglan LI, Senara S, Ibrahim ME, Khalifa I, Owaidy RE, Fakharany NE, Mohammed RHA, Gheita TA; Egyptian College of Rheumatology (ECR) COVID-19 Study Group. Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt. Rheumatol Int 2021;41:1607-16. [PMID: 34244818 DOI: 10.1007/s00296-021-04941-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Yiu ZZN, Harding-Oredugba G, Griffiths CEM, Warren RB, McMullen E, Hunter HJA. Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. Br J Dermatol 2021;185:441-3. [PMID: 33730411 DOI: 10.1111/bjd.20062] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van Geel N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies? Drugs R D 2021;21:341-50. [PMID: 34106430 DOI: 10.1007/s40268-021-00349-0] [Reference Citation Analysis]